German WPC specialist Naturinform engages experienced export director and manager
Redwitz a.d. Rodach
German WPC (Wood-Polymer-Composite) specialist Naturinform increases its international business and further expands its market presence. By engaging Edward Robinson as the Director of International Business Development, the enterprise relies on an experienced industry specialist in order to strategically advance its export business even more. A native of England, Robinson boasts with nearly 20 years of experience in the European composites industry, recently holding the same leading position at UPM-Profi.
"Our sustainable wood composite material profiles have become increasingly popular around the globe. The great interest international visitors showed to our products at the world's leading trade fair BAU in January confirms that our opportunities in the global market are substantial. With Edward Robinson, we won over a proven expert who will support us in our efforts to further expand our export activities", says Horst Walther, Managing Partner of Naturinform.
In addition to that, Yves Houbrechts joined Edward Robinson's team as the Sales Manager for the Netherlands and Belgium region. Houbrechts also has profound experience in the composite materials market and will make significant contributions to strengthen Naturinform's presence in these markets.
According to Horst Walther, this internationalisation is a key strategy for future growth of the enterprise: "By integrating UPM products and expanding our own product series for co-extruded decking boards, we are laying the groundwork for permanently consolidating our position in the international market and opening up new business opportunities."
Managing Director Pia Hobeck underlines the importance of innovation, product diversity and sustainability for their corporate strategy: "As a leading provider of WPC solutions with environment-friendly and versatile products, we will remain true to our strategy of inspiring even foreign markets and thus successfully growing in the long run."
Presscontact:
PR I KOMMUNIKATION
Images
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
VORN Bioenergy announces appointments to leadership team15.1.2026 10:58:53 CET | Press Release
Regensburg. VORN Bioenergy today announces the appointment of Jörg Lennertz as Chief Executive Officer and Manuel Fernández Durán as Chief Financial Officer. Jörg and Manuel together with Michael Wallis Olausson form the new management team. Jörg Lennertz is an experienced leader in the bioenergy sector. Joining VORN Bioenergy from Uniper, he played a key role in building the company’s multi-gigawatt European renewable energy business. Jörg’s experience, from project development through to execution as well as in scaling up, will be valuable for implementing VORN Bioenergy’s ambitious growth strategy across Germany, Italy, the Iberian Peninsula and Poland. Jörg Lennertz succeeds Thorsten Holl who over the past three years, restructured the company, repositioned it, and established its foundations for growth. Jörg Lennertz says: “VORN Bioenergy has decades of experience in realizing and commercially optimizing biomethane assets, and I’m delighted to join them as they enter a new phase o
Vyoma’s first Space Domain Awareness satellite has reached orbit13.1.2026 12:34:15 CET | Press Release
Munich, 13. January 2026 - Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has launched its pioneering surveillance satellite, Flamingo-1, on Sunday, January 11th, 2026 from Vandenberg Space Force Base, California, USA. It was launched aboard the Twilight rideshare mission with SpaceX via Germany-based launch integrator Exolaunch. The satellite was deployed to its operational Sun-synchronous orbit of approximately 500-km in altitude. This marks a significant achievement for the company, which patented the operational concept of an optimized SDA mission. Flamingo-1, equipped with an optical sensor for space-based space surveillance, is a gamechanger for Europe, strengthening SDA efforts directly from orbit. The advanced optical instrument will detect, track and characterize space objects, such as debris and other satellites. Crucially, it will allow Vyoma and its customers to follow up on manoeuvring objects and derive insights into adversary actions
ORTEC expands German healthcare footprint with strategic acquisition of Klages & Partner13.1.2026 09:00:00 CET | Press Release
Zoetermeer, Netherlands - 13 January 2026 - Acquisition adds over 200 healthcare customers and sector-specific workforce management expertise to ORTEC’s portfolio
ESSL leading study to find where and why damaging hail is getting worse12.1.2026 13:38:03 CET | Press Release
Wiener Neustadt, Austria jan 12, 2026 - First comprehensive global study of very large hail in a changing climate reveals contrasting trends and different causes.
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press Release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom